Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).

The sensitivity analysis using Fine-Gray approach instead of cause-specific Cox demonstrated a similar trend for OMA versus JAKi, although the risk of discontinuation for AEs did not reach statistical significance (subdistribution HR (sHR) 1.08, 95% CI 0.98 to 1.19).

also in 111,027 other papers